The receptor for advanced glycation end products and risk of peripheral arterial disease, amputation or death in type 2 diabetes: a population-based cohort study

Cardiovascular Diabetology

Kerstin Brismar²  Jesper Swedenborg³  Lars Kärvestedt³  Jonas Malmstedt¹ 

[1] Division of Vascular Surgery, Department of Surgery, South Hospital, Stockholm, 118 83, Sweden;Karolinska University Hospital, Stockholm, Sweden;Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden

关键词: Population studies;    Arteriosclerosis;    Diabetes mellitus;    Peripheral arterial disease;   

Others  :  1221204
DOI  :  10.1186/s12933-015-0257-5

 received in 2015-04-16, accepted in 2015-07-16,  发布年份 2015

【 摘 要 】

Background

Patients with type 2 diabetes have a high risk for early and extensive development of peripheral arterial disease (PAD) and this excess risk is not explained by increased burden of traditional atherosclerotic risk factors. Activation of the receptor for advanced glycation end products (RAGE) could be one additional mechanism for accelerated PAD and increased risk for amputation and death. We investigated the association between RAGE plasma components and the risk for PAD, amputation and death in patients with type 2 diabetes. We also estimated the rate of amputation-free survival and survival without PAD.

Methods

We investigated if plasma levels of carboxymethyl-lysine, S100A12 and endosecretory RAGE (esRAGE) were associated with two endpoints: survival without development of PAD and survival without amputation in a 12 years prospective population-based cohort of 146 patients with type 2 diabetes, free from PAD at inclusion. Influence of baseline plasma levels of RAGE ligands (individually and combined by a RAGE-score) were evaluated for both endpoints in the Cox-regression analysis.

Results

106 patients survived without amputation and 93 survived without signs of PAD during follow up. Higher levels of S100A12 and RAGE-score were associated with increased risk for amputation or death, hazard ratios (HR) 1.29; 95% confidence interval (CI) [1.04, 1.59] and 1.79; 95% CI [1.07, 2.99] and with increased risk for PAD or death, HR 1.22; 95% CI [1.00, 1.49] and 1.56; [1.00, 2.44] after adjustment for age and sex. The effect was decreased after adjustment for Framingham cardiovascular disease score: risk for amputation or death, HR 1.17; 95% CI [0.94, 1.46] and 1.54; [0.95, 2.49], and risk for PAD or death, HR 1.12; 95% CI [0.91, 1.38] and 1.38; [0.91, 2.11] for S100A12 and RAGE-score respectively. The incidence for amputation or death was 2.8 per 100 person-years; 95% CI [2.0, 3.7] and the incidence rate for PAD or death was 3.6 per 100 person-years; 95% CI [2.7, 4.8].

Conclusion

Higher plasma levels of S100A12 and the combined effect (RAGE-score) of esRAGE, carboxymethyl-lysine and S100A12 seem to be associated with shorter PAD- and amputation-free survival in patients with type 2 diabetes. This may indicate a role for S100A12 in PAD by activation of the RAGE system.

【 授权许可】

   
2015 Malmstedt et al.

【 图 表 】

Fig.1.

Fig.2.

【 参考文献 】

• [1]Leibson CL, Ransom JE, Olson W, Zimmerman BR, O’Fallon WM, Palumbo PJ. Peripheral arterial disease, diabetes, and mortality. Diabetes Care. 2004; 27(12):2843-2849.
• [2]Tapp RJ, Balkau B, Shaw JE, Valensi P, Cailleau M, Eschwege E et al.. Association of glucose metabolism, smoking and cardiovascular risk factors with incident peripheral arterial disease: the DESIR study. Atherosclerosis. 2007; 190(1):84-89.
• [3]Selvin E, Wattanakit K, Steffes MW, Coresh J, Sharrett AR. HbA1c and peripheral arterial disease in diabetes: the atherosclerosis risk in communities study. Diabetes Care. 2006; 29(4):877-882.
• [4]Ogren M, Hedblad B, Engstrom G, Janzon L. Prevalence and prognostic significance of asymptomatic peripheral arterial disease in 68-year-old men with diabetes. Results from the population study ‘Men born in 1914’ from Malmo, Sweden. Eur J Vasc Endovasc Surg. 2005; 29(2):182-189.
• [5]Adler AI, Stevens RJ, Neil A, Stratton IM, Boulton AJ, Holman RR. UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care. 2002; 25(5):894-899.
• [6]Zander E, Heinke P, Reindel J, Kohnert KD, Kairies U, Braun J et al.. Peripheral arterial disease in diabetes mellitus type 1 and type 2: are there different risk factors? Vasa. 2002; 31(4):249-254.
• [7]Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassai B et al.. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ. 2011; 343:d4169.
• [8]MacGregor AS, Price JF, Hau CM, Lee AJ, Carson MN, Fowkes FG. Role of systolic blood pressure and plasma triglycerides in diabetic peripheral arterial disease. The Edinburgh Artery Study. Diabetes Care. 1999; 22(3):453-458.
• [9]Major AS, Harrison DG. What fans the fire: insights into mechanisms of inflammation in atherosclerosis and diabetes mellitus. Circulation. 2011; 124(25):2809-2811.
• [10]Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA, Linz P et al.. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010; 362(17):1563-1574.
• [11]Neeper M, Schmidt A, Brett J, Yan S, Wang F, Pan Y et al.. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem. 1992; 267(21):14998-15004.
• [12]Schmidt AM, Hofmann M, Taguchi A, Yan SD, Stern DM. RAGE: a multiligand receptor contributing to the cellular response in diabetic vasculopathy and inflammation. Semin Thromb Hemost. 2000; 26(5):485-493.
• [13]Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med. 1988; 318(20):1315-1321.
• [14]Reddy S, Bichler J, Wells-Knecht KJ, Thorpe SR, Baynes JW. N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry. 1995; 34(34):10872-10878.
• [15]Uribarri J, Stirban A, Sander D, Cai W, Negrean M, Buenting CE et al.. Single oral challenge by advanced glycation end products acutely impairs endothelial function in diabetic and nondiabetic subjects. Diabetes Care. 2007; 30(10):2579-2582.
• [16]Kislinger T, Fu C, Huber B, Qu W, Taguchi A, Du Yan S et al.. N epsilon-(Carboxymethyl)Lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem. 1999; 274(44):31740-31749.
• [17]Hsieh HL, Schafer BW, Weigle B, Heizmann CW. S100 protein translocation in response to extracellular S100 is mediated by receptor for advanced glycation endproducts in human endothelial cells. Biochem Biophys Res Commun. 2004; 316(3):949-959.
• [18]Koyama H, Shoji T, Fukumoto S, Shinohara K, Shoji T, Emoto M et al.. Low circulating endogenous secretory receptor for AGEs predicts cardiovascular mortality in patients with end-stage renal disease. Arterioscler Thromb Vasc Biol. 2006; 27:147-153.
• [19]Kosaki A, Hasegawa T, Kimura T, Iida K, Hitomi J, Matsubara H et al.. Increased plasma S100A12 (EN-RAGE) levels in patients with type 2 diabetes. J Clin Endocrinol Metab. 2004; 89(11):5423-5428.
• [20]Mohamed AK, Bierhaus A, Schiekofer S, Tritschler H, Ziegler R, Nawroth PP. The role of oxidative stress and NF-kappaB activation in late diabetic complications. BioFactors. 1999; 10(2–3):157-167.
• [21]Kislinger T, Tanji N, Wendt T, Qu W, Lu Y, Ferran LJ et al.. Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol. 2001; 21(6):905-910.
• [22]Basta G, Lazzerini G, Massaro M, Simoncini T, Tanganelli P, Fu C et al.. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation. 2002; 105(7):816-822.
• [23]Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res. 1999; 84(5):489-497.
• [24]Cheng C, Tsuneyama K, Kominami R, Shinohara H, Sakurai S, Yonekura H et al.. Expression profiling of endogenous secretory receptor for advanced glycation end products in human organs. Mod Pathol. 2005; 18(10):1385-1396.
• [25]Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, Li H et al.. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J. 2003; 370(Pt 3):1097-1109.
• [26]Katakami N, Matsuhisa M, Kaneto H, Matsuoka TA, Sakamoto K, Nakatani Y et al.. Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications. Diabetes Care. 2005; 28(11):2716-2721.
• [27]Koyama H, Shoji T, Yokoyama H, Motoyama K, Mori K, Fukumoto S et al.. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol. 2005; 25(12):2587-2593.
• [28]Basta G, Sironi AM, Lazzerini G, Del Turco S, Buzzigoli E, Casolaro A et al.. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J Clin Endocrinol Metab. 2006; 91(11):4628-4634.
• [29]Catalano M, Cortelazzo A, Santi R, Contino L, Demicheli M, Yilmaz Y et al.. The Pro12Ala polymorphism of peroxisome proliferator-activated receptor-gamma2 gene is associated with plasma levels of soluble RAGE (Receptor for Advanced Glycation Endproducts) and the presence of peripheral arterial disease. Clin Biochem. 2008; 41(12):981-985.
• [30]Mahajan N, Malik N, Bahl A, Dhawan V. Receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in non-diabetic subjects with pre-mature coronary artery disease. Atherosclerosis. 2009; 207(2):597-602.
• [31]Burke AP, Kolodgie FD, Zieske A, Fowler DR, Weber DK, Varghese PJ et al.. Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler Thromb Vasc Biol. 2004; 24(7):1266-1271.
• [32]Shiotsu Y, Mori Y, Hatta T, Maki N, Iida K, Matsuoka E et al.. Plasma S100A12 levels and peripheral arterial disease in end-stage renal disease. Nephron Extra. 2011; 1(1):242-250.
• [33]Nin JW, Jorsal A, Ferreira I, Schalkwijk CG, Prins MH, Parving HH et al.. Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. Diabetes Care. 2011; 34(2):442-447.
• [34]Karvestedt L, Martensson E, Grill V, Elofsson S, von Wendt G, Hamsten A et al.. The prevalence of peripheral neuropathy in a population-based study of patients with type 2 diabetes in Sweden. J Diabetes Complications. 2011; 25(2):97-106.
• [35]Karvestedt L, Martensson E, Grill V, Elofsson S, von Wendt G, Hamsten A et al.. Peripheral sensory neuropathy associates with micro- or macroangiopathy: results from a population-based study of type 2 diabetic patients in Sweden. Diabetes Care. 2009; 32(2):317-322.
• [36]Breslow NE, Day NE. Statistical methods in cancer research. Volume II–the design and analysis of cohort studies. IARC Sci Publ. 1987; 82:1-406.
• [37]Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998; 17(8):857-872.
• [38]Analytical Tools for Public Health: Commonly used public health statistics and their confidence intervals. http://www. apho.org.uk/resource/view.aspx?RID=47240
• [39]D’Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM et al.. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008; 117(6):743-753.
• [40]Statistics. http://www. britannica.com/EBchecked/topic/564172/statistics
• [41]Boyles AL, Harris SF, Rooney AA, Thayer KA. Forest plot viewer: a new graphing tool. Epidemiology. 2011; 22(5):746-747.
• [42]Nakashima A, Carrero JJ, Qureshi AR, Miyamoto T, Anderstam B, Barany P et al.. Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patients. Clin J Am Soc Nephrol. 2010; 5(12):2213-2219.
• [43]Shiotsu Y, Mori Y, Nishimura M, Sakoda C, Tokoro T, Hatta T et al.. Plasma S100A12 level is associated with cardiovascular disease in hemodialysis patients. Clin J Am Soc Nephrol. 2011; 6(4):718-723.
• [44]Callaghan BC, Feldman E, Liu J, Kerber K, Pop-Busui R, Moffet H et al.. Triglycerides and amputation risk in patients with diabetes: ten-year follow-up in the DISTANCE study. Diabetes Care. 2011; 34(3):635-640.
• [45]Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Boren J, Catapano AL et al.. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011; 32(11):1345-1361.
• [46]Vlassara H, Striker GE. AGE restriction in diabetes mellitus: a paradigm shift. Nat Rev Endocrinol. 2011; 7(9):526-539.
• [47]Takenaka K, Yamagishi S, Matsui T, Nakamura K, Imaizumi T. Role of advanced glycation end products (AGEs) in thrombogenic abnormalities in diabetes. Curr Neurovasc Res. 2006; 3(1):73-77.
• [48]Ishibashi Y, Matsui T, Ueda S, Fukami K, Yamagishi S. Advanced glycation end products potentiate citrated plasma-evoked oxidative and inflammatory reactions in endothelial cells by up-regulating protease-activated receptor-1 expression. Cardiovasc Diabetol. 2014; 13:60. BioMed Central Full Text
• [49]Ishibashi Y, Matsui T, Maeda S, Higashimoto Y, Yamagishi S. Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor. Cardiovasc Diabetol. 2013; 12:125. BioMed Central Full Text
• [50]Fukushima Y, Daida H, Morimoto T, Kasai T, Miyauchi K, Yamagishi S et al.. Relationship between advanced glycation end products and plaque progression in patients with acute coronary syndrome: the JAPAN-ACS sub-study. Cardiovasc Diabetol. 2013; 12:5. BioMed Central Full Text
• [51]Skrha J, Muravska A, Flekac M, Horova E, Novak J, Novotny A et al.. Fructosamine 3-kinase and glyoxalase I polymorphisms and their association with soluble RAGE and adhesion molecules in diabetes. Physiol Res. 2014; 63 Suppl 2:S283-S291.
• [52]Kallio M, Forsblom C, Groop PH, Groop L, Lepantalo M. Development of new peripheral arterial occlusive disease in patients with type 2 diabetes during a mean follow-up of 11 years. Diabetes Care. 2003; 26(4):1241-1245.
• [53]Wattanakit K, Folsom AR, Selvin E, Weatherley BD, Pankow JS, Brancati FL et al.. Risk factors for peripheral arterial disease incidence in persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis. 2005; 180(2):389-397.
• [54]Groenwold RH, Klungel OH, Grobbee DE, Hoes AW. Selection of confounding variables should not be based on observed associations with exposure. Eur J Epidemiol. 2011; 26(8):589-593.
• [55]Stang A, Poole C, Kuss O. The ongoing tyranny of statistical significance testing in biomedical research. Eur J Epidemiol. 2010; 25(4):225-230.
• [56]Cumming G, Finch S. Inference by eye: confidence intervals and how to read pictures of data. Am Psychol. 2005; 60(2):170-180.
• [57]Cumming G. The new statistics: why and how. Psychol Sci. 2014; 25(1):7-29.